Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells

Protein Expression and Purification

Volumn 59, Issue 2, 2008, Pages 223-231

  Du, Sean X ^a   Xu, Li ^a   Viswanathan, Sridhar ^a   Whalen, Robert G ^a  

^a MAXYGEN INC   (United States)

Author keywords

CHO K1 cells; Envelope; Expression; gp120; HIV 1; Protease; Protease inhibitors; V3

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE FRAGMENT; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; TRYPSIN;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMISTRY; CHO CELL; CRICETULUS; CULTURE MEDIUM; DRUG EFFECT; HAMSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CRICETINAE; CRICETULUS; CULTURE MEDIA; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TRYPSIN;

CRICETULUS GRISEUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 43049092213     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2008.02.002     Document Type: Article

References (37)

1. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., and Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 (2001) 8340-8347
2. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000) 207-210
3. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., and Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76 (2002) 4634-4642
4. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., Martin L., Vita C., Zhu P., Roux K.H., Vojtech L., D C.M., Donnelly J., Ulmer J.B., and Barnett S.W. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77 (2003) 11244-11259
5. Moore J.P., Parren P.W., and Burton D.R. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J. Virol. 75 (2001) 5721-5729
6. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., Wu X., Shaw G.M., Connors M., Wyatt R.T., and Mascola J.R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13 (2007) 1032-1034
7. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905
8. Sharon M., Kessler N., Levy R., Zolla-Pazner S., Gorlach M., and Anglister J. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb.) 11 (2003) 225-236
9. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., and Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293 (2001) 1155-1159
10. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., and Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 (2003) 2065-2071
11. Burton D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2 (2002) 706-713
12. Pantophlet R., and Burton D.R. Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends Mol. Med. 9 (2003) 468-473
13. Hartley O., Klasse P.J., Sattentau Q.J., and Moore J.P. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 21 (2005) 171-189
14. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., and Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 310 (2005) 1025-1028
15. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
16. Conley A.J., Gorny M.K., Kessler II J.A., Boots L.J., Ossorio-Castro M., Koenig S., Lineberger D.W., Emini E.A., Williams C., and Zolla-Pazner S. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68 (1994) 6994-7000
17. Clements G.J., Price-Jones M.J., Stephens P.E., Sutton C., Schulz T.F., Clapham P.R., McKeating J.A., McClure M.O., Thomson S., Marsh M., et al. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?. AIDS Res. Hum. Retroviruses 7 (1991) 3-16
18. Huang C.C., Lam S.N., Acharya P., Tang M., Xiang S.H., Hussan S.S., Stanfield R.L., Robinson J., Sodroski J., Wilson I.A., Wyatt R., Bewley C.A., and Kwong P.D. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317 (2007) 1930-1934
19. Gu R., Westervelt P., and Ratner L. Role of HIV-1 envelope V3 loop cleavage in cell tropism. AIDS Res. Hum. Retroviruses 9 (1993) 1007-1015
20. Kido H., Fukutomi A., and Katunuma N. A novel membrane-bound serine esterase in human T4(+)-lymphocytes is a binding protein of envelope glycoprotein gp120 of HIV-1. Biomed. Biochim. Acta 50 (1991) 781-789
21. Stephens P.E., Clements G., Yarranton G.T., and Moore J.P. A chink in HIV's armour?. Nature 343 (1990) 219
22. Kido H., Fukutomi A., and Katunuma N. A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. Purification and characterization. J. Biol. Chem. 265 (1990) 21979-21985
23. Avril L.E., Di Martino-Ferrer M., Barin F., and Gauthier F. Interaction between a membrane-associated serine proteinase of U-937 monocytes and peptides from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) gp120 envelope glycoprotein. FEBS Lett. 317 (1993) 167-172
24. Niwa Y., Yano M., Futaki S., Okumura Y., and Kido H. T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120. Eur. J. Biochem. 237 (1996) 64-70
25. Lasky L.A., Groopman J.E., Fennie C.W., Benz P.M., Capon D.J., Dowbenko D.J., Nakamura G.R., Nunes W.M., Renz M.E., and Berman P.W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233 (1986) 209-212
26. Scandella C.J., Kilpatrick J., Lidster W., Parker C., Moore J.P., Moore G.K., Mann K.A., Brown P., Coates S., Chapman B., et al. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS Res. Hum. Retroviruses 9 (1993) 1233-1244
27. Rhodes A.D., Spitali M., Hutchinson G., Rud E.W., and Stephens P.E. Expression, characterization and purification of simian immunodeficiency virus soluble, oligomerized gp160 from mammalian cells. J. Gen. Virol. 75 Pt. 1 (1994) 207-213
28. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196 (1987) 947-950
29. Haas J., Park E.C., and Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6 (1996) 315-324
30. Schulz T.F., Reeves J.D., Hoad J.G., Tailor C., Stephens P., Clements G., Ortlepp S., Page K.A., Moore J.P., and Weiss R.A. Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage. AIDS Res. Hum. Retroviruses 9 (1993) 159-166
31. Berman P.W., Gregory T.J., Riddle L., Nakamura G.R., Champe M.A., Porter J.P., Wurm F.M., Hershberg R.D., Cobb E.K., and Eichberg J.W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345 (1990) 622-625
32. Berman P.W., Groopman J.E., Gregory T., Clapham P.R., Weiss R.A., Ferriani R., Riddle L., Shimasaki C., Lucas C., Lasky L.A., et al. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 85 (1988) 5200-5204
33. Keil B. Specificity of Proteolysis (1992), Springer-Verlag, Berlin, Heidelberg, NewYork
34. Haynes B.F., Ma B., Montefiori D.C., Wrin T., Petropoulos C.J., Sutherland L.L., Scearce R.M., Denton C., Xia S.M., Korber B.T., and Liao H.X. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 345 (2006) 44-55
35. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
36. Clouse K.A., Cosentino L.M., Weih K.A., Pyle S.W., Robbins P.B., Hochstein H.D., Natarajan V., and Farrar W.L. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J. Immunol. 147 (1991) 2892-2901
37. Jeffs S.A., McKeating J., Lewis S., Craft H., Biram D., Stephens P.E., and Brady R.L. Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J. Gen. Virol. 77 Pt. 7 (1996) 1403-1410